Prognosis & follow-up · 7 min read

Follow-up, Recurrence and Second Primary Tumours

What a surveillance schedule looks like after head and neck cancer, which symptoms need urgent review, and why second primary tumours matter for patients with tobacco or HPV-related disease.

Reviewed: 8 November 2026 By: Xiangpeng Liu, MD FAQ: 4 questions Sources: 4
Quick answer

NCCN survivorship guidance recommends review every 1–3 months in year one, every 2–6 months in year two, every 4–8 months in years three to five, and annually thereafter, with a full head and neck examination and endoscopy at each visit. Most recurrences appear within the first two to five years; second primary tumours remain a lifelong risk, especially for continuing smokers.

What is a typical follow-up schedule?

Baseline imaging of the primary site and neck within six months of treatment is recommended for advanced T or N disease. Routine repeated imaging without symptoms or signs is not recommended in most guidelines, because it rarely detects curable recurrence earlier than a good clinical examination. TSH is checked every six to twelve months if the neck was irradiated.

Time after treatmentVisit frequencyTypical content
Year 1Every 1–3 monthsSymptom review, head and neck exam, endoscopy, nutrition/swallow check
Year 2Every 2–6 monthsSame, plus dental and thyroid review
Years 3–5Every 4–8 monthsSame, with decreasing imaging
After year 5AnnuallySurveillance, late effects, second-primary prevention

Which condition-specific tests are added?

  • Nasopharyngeal carcinoma: serial plasma EBV DNA, nasopharyngoscopy and periodic MRI of the nasopharynx and neck.
  • Differentiated thyroid cancer: thyroglobulin with anti-thyroglobulin antibodies, neck ultrasound, TSH/free T4; calcitonin and CEA for medullary cancer.
  • HPV-associated oropharyngeal cancer: careful nodal and tonsil/base-of-tongue examination; investigational HPV DNA blood tests are not yet standard surveillance.
  • Head and neck skin cancer: full skin examination, nodal/parotid palpation and lifelong sun protection.

What symptoms should trigger an earlier visit?

  • A new or enlarging neck lump, or new swelling of the face or tongue
  • New hoarseness, difficulty swallowing, breathing change or coughing up blood
  • Persistent pain, new numbness, facial weakness or unexplained ear pain
  • A new oral ulcer or patch, or a non-healing area where a tooth was extracted
  • Unexplained weight loss, a persistent cough or new bone pain
  • Recurrent nosebleeds, unilateral nasal blockage or double vision (nasopharyngeal recurrence)

Why do second primary tumours matter?

The entire upper aerodigestive tract is exposed to the same carcinogens — the concept of "field cancerisation". A person cured of one tobacco-related head and neck cancer has an ongoing risk of a new cancer in the mouth, throat, larynx, oesophagus or lung. Continued smoking roughly sustains that risk; cessation is the most effective intervention, together with prompt evaluation of any new symptom and age-appropriate lung screening where available.

Frequently asked questions

How are most recurrences found?

By symptoms and clinical examination during scheduled follow-up, not by routine scans. This is why attending follow-up visits and reporting new symptoms promptly matters more than repeated imaging.

Can a recurrence still be treated curatively?

Sometimes. A local or regional recurrence after initial treatment may be amenable to salvage surgery, re-irradiation or, in selected nasopharyngeal cases, endoscopic skull-base resection. Early detection and good performance status are the main determinants.

Do I need lifelong follow-up?

Yes for most patients. Late recurrence (adenoid cystic carcinoma, thyroid cancer), second primary tumours and late treatment effects (hypothyroidism, stricture, osteoradionecrosis, dental disease) can appear many years later.

What should I bring to a follow-up visit after treatment abroad?

Your operative and pathology reports, radiotherapy dose sheet, chemotherapy and immunotherapy cycle record, baseline post-treatment imaging, current medication list and the written surveillance plan. Without these, a local team may have to repeat tests unnecessarily.

Sources for this guide

  1. NCCN Guidelines for Patients: Head and Neck Cancers National Comprehensive Cancer Network · 2025
  2. About Head and Neck Cancer American Cancer Society · 2025
  3. Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities Frontiers / British Journal of Biomedical Science partnership · 2025 · 83.3% of the 120,434 global NPC cases in 2022 occurred in Asia.
  4. Thyroid Cancer (patient information) US National Cancer Institute · 2025

All references used on this site →

Written and medically reviewed by Xiangpeng Liu, MD

Associate Chief Physician, ENT & Head/Neck Surgery · Chenzhou First People’s Hospital, Chenzhou, Hunan, China

Over 10 years of clinical practice and 4,000+ ENT and head/neck operations. Content is reviewed against GLOBOCAN 2022 / IARC data and current NCCN and NCI patient guidance. Last reviewed 8 November 2026.

Editorial policy & reviewer credentials · All sources

Applying this to your own case?

Start with a remote review of your records, then compare the written plan with the options you have at home.

Records checklist How to compare plans

Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.